I suspect the market has also been confused by the new AASB 16 numbers. revenue in half 2 was flat even with acqs, U EBITDA up about 15%, hy was up about 13.5%, with death rate in half 2 up around 4.5% ish based on IVC figures of 2.9% FY.
I suspect the market has also been confused by the new AASB 16...
Add to My Watchlist
What is My Watchlist?